Literature DB >> 30586666

Study of the adoptive immunotherapy on rheumatoid arthritis with Thymus-derived invariant natural killer T cells.

Dongzhi Chen1, Huifang Liu1, Yuanyuan Wang1, Shengde Chen1, Jialin Liu1, Wenjuan Li1, Haiyang Dou1, Wenguang Hou2, Ming Meng3.   

Abstract

BACKGROUND: The therapeutic effect of adoptive infusion of specific thymus-derived invariant natural killer T (iNKT) cells in a mouse model of rheumatoid arthritis (RA) was observed, and the mechanism of cellular immunotherapy was preliminarily explored.
METHODS: Thymus-derived iNKT cells were infused to RA model mice, with α-GalCer as a positive control. Then, ankle swelling was examined, as well as inflammatory cell infiltration to the joint tissue (hematoxylin-eosin [H&E] staining). Flow cytometry (FCM) was used to assess iNKT cell and helper T lymphocyte (Th) subsets. Serum cytokine levels were determined with cytometric bead array (CBA), with protein expression levels of related transcription factors assessed by Western blot.
RESULTS: The joint swelling in RA model animals were significantly improved in the cell therapy and α-GalCer positive control groups (P < 0.05). In addition, iNKT frequencies in peripheral blood, the thymus and spleen were increased significantly (P < 0.05). Meanwhile, iNKT1 subset frequencies in the thymus and spleen were decreased, as well as splenic Th1 and Th17 cell subset rates, and serum TNF-α, IFN-γ and IL-6 levels. The rates of iNKT2 and Th2 subsets as well as IL-4 and IL-10 levels were increased (P < 0.05). Thymus GATA-3 and splenic PLZF protein levels were increased (P < 0.05).
CONCLUSIONS: Adoptive infusion of thymus-derived iNKT cells exerts therapeutic effects in RA mice by increasing iNKT frequency, altering the proportions of iNKT cell subsets, correcting Th cell subset imbalance and reducing the amounts of inflammatory cytokines.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Cell adoptive therapy; Cytokines; Rheumatoid arthritis; Th1/Th2/Th17; Transcription factor; iNKT1/iNKT2

Mesh:

Substances:

Year:  2018        PMID: 30586666     DOI: 10.1016/j.intimp.2018.12.040

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  6 in total

1.  Methylation of H3K27 and H3K4 in key gene promoter regions of thymus in RA mice is involved in the abnormal development and differentiation of iNKT cells.

Authors:  Ming Meng; Huifang Liu; Shengde Chen; Huijuan Zhao; Xiang Gao; Jingnan Zhang; Dongzhi Chen
Journal:  Immunogenetics       Date:  2019-07-11       Impact factor: 2.846

Review 2.  Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases.

Authors:  Jinsha Liu; Joey Paolo Ting; Shams Al-Azzam; Yun Ding; Sepideh Afshar
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

Review 3.  Immunoengineering the next generation of arthritis therapies.

Authors:  Molly Klimak; Robert J Nims; Lara Pferdehirt; Kelsey H Collins; Natalia S Harasymowicz; Sara J Oswald; Lori A Setton; Farshid Guilak
Journal:  Acta Biomater       Date:  2021-04-03       Impact factor: 8.947

4.  Sus Scrofa immune tissues as a new source of bioactive substances for skin wound healing.

Authors:  Alexandr Basov; Liliya Fedulova; Ekaterina Vasilevskaya; Ekaterina Trofimova; Nataliya Murashova; Stepan Dzhimak
Journal:  Saudi J Biol Sci       Date:  2020-12-21       Impact factor: 4.219

5.  Migration, Distribution, and Safety Evaluation of Specific Phenotypic and Functional Mouse Spleen-Derived Invariant Natural Killer T2 Cells after Adoptive Infusion.

Authors:  Dongzhi Chen; Wenbin Xu; Jingfang Teng; Huifang Liu; Yuanyuan Wang; Yan Wang; Shujie Cheng; Ming Meng
Journal:  Mediators Inflamm       Date:  2021-12-08       Impact factor: 4.711

6.  Chemokine Receptor 5 Antagonism Causes Reduction in Joint Inflammation in a Collagen-Induced Arthritis Mouse Model.

Authors:  Mushtaq A Ansari; Ahmed Nadeem; Saleh A Bakheet; Sabry M Attia; Mudassar Shahid; Faris S Alyousef; Mohammed A Alswailem; Mohammed Alqinyah; Sheikh F Ahmad
Journal:  Molecules       Date:  2021-03-25       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.